• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

PCV13: Effective Against First-Episode CAP in Older Adults

Slideshow

The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
Respiratory Virus Season 2024-2025: Expert Insights to Help Primary Care Prepare

Respiratory Virus Season 2024-2025: Expert Insights to Help Primary Care Prepare

Sydney Jennings
November 11th 2024
Article

Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose

Sydney Jennings
October 30th 2024
Article

Your daily dose of the clinical news you may have missed.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 Years / image credit ©CDC

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 from 65 Years

Grace Halsey
October 24th 2024
Article

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.

Data for Arexvy Show Vaccine Efficacy Through 3 RSV Seasons in Older Adults/ image credit - gsk logo: ©desertsands/stock.adobe.com

New Data for Arexvy Show Vaccine Efficacy Through 3 RSV Seasons in Older Adults

Grace Halsey
October 9th 2024
Article

Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.

© 2024 MJH Life Sciences

All rights reserved.